Ser63
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser63  -  STMN1 (human)

Site Information
AAEERRksHEAEVLk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448557

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 46 , 68 , 71 , 72 ) , [32P] bio-synthetic labeling ( 72 , 76 ) , immunoassay ( 11 ) , immunoprecipitation ( 4 ) , mass spectrometry ( 5 , 6 , 9 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 , 27 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 47 , 48 , 49 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 72 , 78 ) , mutation of modification site ( 4 , 46 , 72 , 75 , 76 ) , phospho-antibody ( 1 , 3 , 4 , 8 , 10 , 11 , 17 , 46 , 68 ) , phosphoamino acid analysis ( 72 ) , phosphopeptide mapping ( 74 , 76 ) , western blotting ( 1 , 3 , 4 , 8 , 10 , 17 , 74 )
Disease tissue studied:
breast cancer ( 9 , 15 , 24 , 25 ) , breast ductal carcinoma ( 15 ) , HER2 positive breast cancer ( 6 ) , luminal A breast cancer ( 6 ) , luminal B breast cancer ( 6 ) , breast cancer, surrounding tissue ( 6 ) , breast cancer, triple negative ( 6 , 15 ) , cervical cancer ( 47 ) , cervical adenocarcinoma ( 47 ) , leukemia ( 1 , 68 , 76 ) , acute myelogenous leukemia ( 68 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 23 ) , acute megakaryoblastic leukemia (M7) ( 23 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 23 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 23 ) , chronic myelogenous leukemia ( 1 , 76 ) , liver cancer ( 10 ) , lung cancer ( 3 , 4 , 8 , 18 , 25 , 34 , 36 , 42 , 44 ) , non-small cell lung cancer ( 3 , 4 , 8 , 25 , 36 , 42 ) , non-small cell lung adenocarcinoma ( 4 , 18 , 34 ) , non-small cell large cell lung carcinoma ( 36 ) , lymphoma ( 68 ) , ovarian cancer ( 15 ) , melanoma skin cancer ( 13 ) , thymic carcinoma ( 35 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 39 ) , A431 (epithelial) ( 78 ) , A498 (renal) ( 41 ) , A549 (pulmonary) ( 4 , 19 ) , AML-193 (monocyte) ( 23 ) , bone marrow ( 68 ) , breast ( 6 , 11 , 15 ) , BT-20 (breast cell) ( 25 ) , BT-474 (breast cell) ( 9 ) , BT-549 (breast cell) ( 25 ) , Calu 6 (pulmonary) ( 25 ) , CMK (megakaryoblast) ( 23 ) , endothelial-aorta ( 26 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 27 ) , Flp-In T-Rex-293 (epithelial) ( 27 ) , GM00130 (B lymphocyte) ( 40 ) , H2009 (pulmonary) ( 25 ) , H2077 (pulmonary) ( 25 ) , H2887 (pulmonary) ( 25 ) , H322M (pulmonary) ( 25 ) , HCC1359 (pulmonary) ( 25 ) , HCC1937 (breast cell) ( 25 ) , HCC2279 (pulmonary) ( 25 ) , HCC366 (pulmonary) ( 25 ) , HCC4006 (pulmonary) ( 25 ) , HCC78 (pulmonary) ( 25 ) , HCC827 (pulmonary) ( 25 ) , HEK293T (epithelial) ( 4 , 12 , 66 ) , HEL (erythroid) ( 23 ) , HeLa (cervical) ( 5 , 10 , 14 , 33 , 38 , 46 , 48 , 51 , 61 , 64 , 65 , 67 , 76 ) , HeLa S3 (cervical) ( 47 ) , HEp-2 (squamous) ( 71 ) , HepG2 (hepatic) ( 10 ) , HOP62 (pulmonary) ( 25 ) , HPAEC (endothelial) ( 17 ) , HUES-9 ('stem, embryonic') ( 37 ) , Jurkat (T lymphocyte) ( 20 , 29 , 30 , 32 , 43 , 49 , 58 , 59 , 60 , 62 , 63 , 74 ) , K562 (erythroid) ( 1 , 22 , 48 , 75 , 76 ) , Kasumi-1 (myeloid) ( 23 ) , KG-1 (myeloid) ( 23 ) , L929 (fibroblast) ( 72 ) , LCLC-103H (pulmonary) ( 25 ) , LOU-NH91 (squamous) ( 25 ) , lung ( 18 , 44 ) , MCF-7 (breast cell) ( 9 , 25 ) , MDA-MB-231 (breast cell) ( 25 ) , MDA-MB-468 (breast cell) ( 25 ) , MKN-45 (gastric) ( 55 , 56 ) , MV4-11 (macrophage) ( 23 ) , NCI-H1299 (pulmonary) ( 3 , 8 ) , NCI-H1395 (pulmonary) ( 25 ) , NCI-H1568 (pulmonary) ( 25 ) , NCI-H157 (pulmonary) ( 25 ) , NCI-H1648 (pulmonary) ( 25 ) , NCI-H1650 (pulmonary) ( 42 ) , NCI-H1666 (pulmonary) ( 25 ) , NCI-H1703 (squamous) ( 53 , 54 ) , NCI-H2030 (pulmonary) ( 25 ) , NCI-H2172 (pulmonary) ( 25 ) , NCI-H322 (pulmonary) ( 25 ) , NCI-H3255 (pulmonary) ( 52 , 57 ) , NCI-H460 (pulmonary) ( 25 ) , NCI-H520 (squamous) ( 25 ) , NCI-H647 (pulmonary) ( 25 ) , NCI-H661 (pulmonary) ( 36 ) , NT2 (testicular) ( 45 ) , ovary ( 15 ) , P31/FUJ (erythroid) ( 23 ) , PC9 (pulmonary) ( 25 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 16 ) , SKBr3 (breast cell) ( 24 ) , thymus ( 35 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 34 ) , U-1810 (pulmonary) ( 34 ) , U-937 (myeloid) [RARA (human), transfection] ( 68 ) , WM239A (melanocyte) ( 13 )

Upstream Regulation
Regulatory protein:
PAK1 (human) ( 17 ) , PIWIL1 (human) ( 10 ) , PRL3B1 (mouse) ( 1 ) , RAC1 (human) ( 17 )
Kinases, in vitro:
PKACA (human) ( 50 , 73 , 77 ) , PKACA (mouse) ( 70 )
Treatments:
angiotensin_2 ( 39 ) , anti-CD2 ( 74 ) , anti-IL-10 ( 3 ) , EGF ( 5 , 67 ) , HGF ( 17 ) , Met_inhibitor ( 17 ) , nocodazole ( 47 , 76 ) , okadaic_acid ( 74 ) , PD98059 ( 8 ) , quinalizarin ( 12 ) , siRNA ( 1 ) , TNF ( 72 )

Downstream Regulation
Effects of modification on STMN1:
activity, inhibited ( 46 , 75 ) , molecular association, regulation ( 69 , 70 , 73 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
apoptosis, altered ( 72 ) , apoptosis, induced ( 1 ) , carcinogenesis, inhibited ( 1 ) , cell cycle regulation ( 68 , 69 , 76 ) , cell growth, inhibited ( 1 ) , cell motility, inhibited ( 1 ) , cytoskeletal reorganization ( 17 , 46 , 50 , 72 , 73 ) , signaling pathway regulation ( 1 , 17 )
Inhibit interaction with:
TUBA1A (cow) ( 70 , 73 ) , TUBA4A (human) ( 69 ) , TUBB (cow) ( 70 , 73 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 11 )

References 

1

Xu J, et al. (2019) PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling. Aging (Albany NY) 11, 7817-7829
31546234   Curated Info

2

Chen S, et al. (2019) Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells. Oncol Rep 41, 2051-2059
30628717   Curated Info

3

Zhao Y, et al. (2018) In vitro neutralization of autocrine IL‑10 affects Op18/stathmin signaling in non‑small cell lung cancer cells. Oncol Rep
30320402   Curated Info

4

Alesi GN, et al. (2016) RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. Oncogene 35, 5412-5421
27041561   Curated Info

5

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

6

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

7

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

8

Lin X, et al. (2016) Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells. Cancer Biother Radiopharm 31, 37-43
26881937   Curated Info

9

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

10

Li C, et al. (2015) PIWIL1 destabilizes microtubule by suppressing phosphorylation at Ser16 and RLIM-mediated degradation of Stathmin1. Oncotarget 6, 27794-804
26317901   Curated Info

11

Kuang XY, et al. (2015) Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients. Oncotarget 6, 22227-38
26087399   Curated Info

12

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

13

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

14

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

15

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

16

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

17

Tian X, et al. (2014) Microtubule dynamics control hgf-induced lung endothelial barrier enhancement. PLoS One 9, e105912
25198505   Curated Info

18

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

19

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

20

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

21

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

22

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

23

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

24

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

25

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

26

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

27

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

28

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

29

Mulhern D (2012) CST Curation Set: 13827; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

30

Mulhern D (2012) CST Curation Set: 13112; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

31

Rikova K (2011) CST Curation Set: 13122; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

32

Mulhern D (2011) CST Curation Set: 13070; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F
Curated Info

33

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

34

Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78
21413766   Curated Info

35

Li Y (2011) CST Curation Set: 10460; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

Rikova K (2011) CST Curation Set: 10897; Year: 2011; Biosample/Treatment: cell line, NCI-H661/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

37

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

38

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

39

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

40

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

41

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

42

Possemato A (2010) CST Curation Set: 9732; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

43

Rikova K (2010) CST Curation Set: 9774; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

44

Rikova K (2010) CST Curation Set: 9770; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

45

Zhou J (2010) CST Curation Set: 9679; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

46

Chen PW, et al. (2010) Regulation of microtubule dynamics through phosphorylation on stathmin by Epstein-Barr virus kinase BGLF4. J Biol Chem 285, 10053-63
20110360   Curated Info

47

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

48

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

49

Guo A (2009) CST Curation Set: 8004; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

50

Manna T, et al. (2009) Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin. J Biol Chem 284, 15640-9
19359244   Curated Info

51

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

52

Moritz A (2008) CST Curation Set: 5781; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

53

Moritz A (2008) CST Curation Set: 5783; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

54

Moritz A (2008) CST Curation Set: 5784; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

55

Moritz A (2008) CST Curation Set: 5776; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

56

Moritz A (2008) CST Curation Set: 5777; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

57

Moritz A (2008) CST Curation Set: 5780; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

58

Zhou J (2008) CST Curation Set: 5473; Year: 2008; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

59

Possemato A (2008) CST Curation Set: 5387; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

60

Possemato A (2008) CST Curation Set: 5274; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

61

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

62

Possemato A (2008) CST Curation Set: 4831; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

63

Zhou J (2008) CST Curation Set: 4705; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

64

McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80
18212344   Curated Info

65

Yu LR, et al. (2007) Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res 6, 4150-62
17924679   Curated Info

66

Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204
17287340   Curated Info

67

Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48
17081983   Curated Info

68

Zada AA, et al. (2006) Proteomic analysis of acute promyelocytic leukemia: PML-RARalpha leads to decreased phosphorylation of OP18 at serine 63. Proteomics 6, 5705-19
17001604   Curated Info

69

Honnappa S, Jahnke W, Seelig J, Steinmetz MO (2006) Control of intrinsically disordered stathmin by multisite phosphorylation. J Biol Chem 281, 16078-83
16554300   Curated Info

70

Steinmetz MO, et al. (2001) Phosphorylation disrupts the central helix in Op18/stathmin and suppresses binding to tubulin. EMBO Rep 2, 505-10
11415983   Curated Info

71

Daub H, et al. (2001) Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J Biol Chem 276, 1677-80
11058583   Curated Info

72

Vancompernolle K, et al. (2000) Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death. J Biol Chem 275, 33876-82
10913145   Curated Info

73

Amayed P, Carlier MF, Pantaloni D (2000) Stathmin slows down guanosine diphosphate dissociation from tubulin in a phosphorylation-controlled fashion. Biochemistry 39, 12295-302
11015208   Curated Info

74

le Gouvello S, Manceau V, Sobel A (1998) Serine 16 of stathmin as a cytosolic target for Ca2+/calmodulin-dependent kinase II after CD2 triggering of human T lymphocytes. J Immunol 161, 1113-22
9686569   Curated Info

75

Larsson N, et al. (1997) Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol 17, 5530-9
9271428   Curated Info

76

Larsson N, et al. (1995) G2/M transition requires multisite phosphorylation of oncoprotein 18 by two distinct protein kinase systems. J Biol Chem 270, 14175-83
7775478   Curated Info

77

Marklund U, et al. (1994) Serine 16 of oncoprotein 18 is a major cytosolic target for the Ca2+/calmodulin-dependent kinase-Gr. Eur J Biochem 225, 53-60
7925472   Curated Info

78

MS This site is one of 509 sites observed by D. Stover et al using MS/FTMS of peptides from lysates of A431 cells grown either in vitro or as xenografts in BALB/c nu/nu mice. These sites were previously unpublished until now (July 27 2006). 66 sites were previously published in: Stover DR, et al. Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts Clin Proteomics 2004 Mar 01; 1(1): 69-80.
Curated Info